Phase 1b results from CRDF second line KRASm CRC now published in Clinical Cancer Research . RP2 1st study CRDF-004, to open soon. Congrats to our co-authors and patients Mayo Clinic Comprehensive Cancer Center Tanios Bekaii-Saab, MD

🏡 RIGGS EXPERIENCE GIVEAWAY 🏡 One winner and their friend will get a FREE round trip to Pinehurst for 2 nights & 2 rounds of golf, PLUS fully scripted travel outfits from @PeterMillar. 5 other winners will be selected to receive scripting golf outfits from Peter Millar & a

Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic #ColorectalCancer: A Single-Arm, Phase II Trial brnw.ch/21wOmCb Daniel Ahn Mayo Clinic Comprehensive Cancer Center Inova Schar Cancer Institute CARTI Arkansas @drjasonstarr Mayo Clinic Hematology-Oncology Fellowship #crcsm

Whole discussion on matterhorn Trial was exactly how it should NOT be at such prime conference Not a single issues with TRIAL discussed in whole presentation ??? Is this perfect Trial? ?? Anyways , audiace ,especially oncology audiences is not naive in today's Era. ASCO

As highlighted below—we need to see OS data. Just 24 hrs ago, CM577 reminded us that DFS benefit doesn’t guarantee OS benefit. Add in the negative KN study, and it’s clear we should pause before widely adopting. FDA has to wait before approving this.